Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06158477 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06158477 · ClinicalTrials.gov record · last posted 2024-11-18

A Clinical Trial Evaluating JYP0035 Capsule Monotherapy in Patients With Advanced Solid Tumors

StatusRecruiting
PhasePhase 1
Started2024-01-01
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The goal of this Phase I clinical trial is to evaluate the safety, tolerability, and pharmacokinetic characteristics of the JYP0035 capsule in patients with advanced solid tumors. The main questions it aims to answer are: * What is the safety profile of JYP0035 when administered to these patients? * How does JYP0035 capsule behave in the body pharmacokinetically? Participants will: * Receive escalating doses of JYP0035 capsule during the dose-escalation phase (PART-1). * Continue with the identified dose in the dose-expansion phase (PART-2). As this is a single-arm study, there is no comparison group.

Amendment record 2 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 2 times since 2023-11-28; most recent amendment 2024-11-15. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2024-11-15
Status change Not Yet Recruiting→Recruitingv2
Trial Details
NCT Number NCT06158477
Lead Sponsor Chengdu JOYO pharma Co., Ltd.
Collaborators: Guangzhou JOYO Pharma Co., Ltd
Conditions Advanced Solid Tumors
Enrollment 75 participants
Start Date 2024-01-01
Primary Completion 2026-12-01 (estimated)
Study Completion 2027-12-01 (estimated)
Updated on ClinicalTrials.gov 2024-11-18